16.1 Age-Specific Pain Assessment Tools & Analgesic Selection

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection

Effective pediatric pain management requires a nuanced understanding of developmental neurobiology, validated behavioral and self-report assessment scales, and age-stratified clinical pharmacology. Historic misconceptions that neonates and young infants do not feel pain due to nervous system immaturity have been thoroughly refuted; in fact, immature descending inhibitory pathways make preterm and term neonates hypersensitive to noxious stimuli. Untreated acute pain in early infancy causes persistent alterations in pain processing, heightened stress responses, and adverse neurodevelopmental outcomes. This section establishes an evidence-based framework for age-specific pain assessment, multimodal non-opioid analgesia, parenteral opioid selection, equianalgesic conversions, and patient-controlled analgesia (PCA) monitoring.

---

Validated Pediatric Pain Assessment Tools

Pain assessment in pediatric patients must be tailored to cognitive capacity, developmental stage, verbal fluency, and clinical setting. Selecting an inappropriate assessment instrument can lead to severe under-treatment of acute pain or iatrogenic opioid overdose.

Developmental Spectrum of Pediatric Pain Assessment Tools:

[Neonates & Preterms]   ──►  N-PASS / CRIES / PIPP-R   (Behavioral + Physiological)
[2 Months to 7 Years]   ──►  FLACC Scale                (Observational Behavioral)
[>= 3 to 4 Years]        ──►  Wong-Baker FACES / FPS-R   (Self-Report Iconographic)
[>= 7 to 8 Years]        ──►  VAS / NRS (0-10)           (Self-Report Numerical / Linear)
[Cognitively Impaired]  ──►  r-FLACC / INCPAD           (Individualized Behavioral)

1. Neonatal Pain, Agitation, and Sedation Scale (N-PASS)

• Target Population: Preterm neonates (as early as 23 weeks gestational age) and term infants up to 100 days of post-natal age.
• Parameters: Assesses 5 clinical criteria: Crying/irritability, Behavior/state, Facial expression, Extremities/tone, and Vital signs (heart rate, respiratory rate, blood pressure, $SpO_2$).
• Scoring Nuance: Features a dual scale: a Pain/Agitation score ranging from 0 to +10 (with +1 point added for premature infants <30 weeks gestation due to blunted physiological responses), where a score >3 warrants non-pharmacologic or pharmacologic intervention; and a Sedation score ranging from 0 to -10 (0 = normal; -10 = deeply sedated).

2. FLACC Scale (Face, Legs, Activity, Cry, Consolability)

• Target Population: Infants and children aged 2 months to 7 years, as well as non-verbal older children unable to self-report.
• Parameters: Evaluates 5 behavioral categories scored from 0 to 2, yielding a total score from 0 to 10:
  • Face: 0 = no particular expression/smile; 1 = occasional grimace/frown, withdrawn; 2 = frequent to constant quivering chin, clenched jaw.
  • Legs: 0 = normal position/relaxed; 1 = uneasy, restless, tense; 2 = kicking or legs drawn up.
  • Activity: 0 = lying quietly, normal position; 1 = squirming, shifting, tense; 2 = arched, rigid, or jerking.
  • Cry: 0 = no cry; 1 = moans/whimpers, occasional complaint; 2 = crying steadily, screams/sobs, frequent complaints.
  • Consolability: 0 = content, relaxed; 1 = reassured by occasional touching/hugging, distractible; 2 = difficult to console or comfort.
• Clinical Action Threshold: Score 1–3 = mild discomfort; 4–6 = moderate pain (requires non-opioid or weak opioid analgesia); 7–10 = severe discomfort/pain (mandates immediate multimodal/parenteral opioid analgesia).
• Revised FLACC (r-FLACC): Incorporates specific individualized behavioral cues identified by parents/caregivers for children with severe developmental delay, cerebral palsy, or cognitive impairment.

3. Wong-Baker FACES Pain Rating Scale & Faces Pain Scale-Revised (FPS-R)

• Target Population: Children aged 3 to 4 years and older who possess symbolic reasoning.
• Mechanism: Displays 6 cartoon or photographic faces illustrating progressive distress from a neutral/smiling face (0 = "No Hurt") to a crying face (10 = "Hurts Worst").
• Clinical Trap: Clinicians must instruct the child to choose the face that depicts how they feel inside, not how their face looks, to avoid conflating sadness/crying with pain intensity.

4. Visual Analog Scale (VAS) & Numerical Rating Scale (NRS)

• Target Population: Children aged 7 to 8 years and older, adolescents, and young adults.
• Mechanism: The NRS utilizes an 11-point horizontal scale (0 = "no pain", 10 = "worst pain imaginable"). Requires abstract numerical understanding and mathematical ordering (recognizing that 6 is greater than 4).

---

Multimodal Non-Opioid Analgesia

Multimodal analgesia combines agents with distinct mechanisms of action to produce additive or synergistic pain relief while significantly reducing opioid requirements ("opioid-sparing effect") and mitigating adverse effects (hypoventilation, nausea, ileus, urinary retention).

Multimodal Analgesic Strategy: Target Receptors & Synergy:

┌────────────────────────────┬─────────────────────────────┬─────────────────────────────────┐
│ Analgesic Class            │ Biochemical Target          │ Primary Pediatric Indication    │
├────────────────────────────┼─────────────────────────────┼─────────────────────────────────┤
│ Acetaminophen (PO/IV)      │ Central COX inhibition, TRPV1│ Baseline mild-moderate pain     │
│ NSAIDs (Ibuprofen/Ketorolac)│ Peripheral/Central COX-1/2  │ Inflammatory & bone/soft tissue │
│ Systemic Opioids           │ Mu-opioid receptor agonism  │ Moderate-severe breakthrough    │
│ Local Anesthetics          │ Voltage-gated Na+ channels  │ Peripheral nerve/wound blocks   │
│ Alpha-2 Agonists / NMDA Ant│ Central alpha-2 / NMDA block│ Hyperalgesia, spasm, tolerance  │
└────────────────────────────┴─────────────────────────────┴─────────────────────────────────┘

1. Acetaminophen (APAP)

Acetaminophen provides central analgesia and antipyresis with negligible peripheral anti-inflammatory activity. Hepatic clearance undergoes profound developmental ontogeny: in neonates and young infants, metabolism occurs predominantly via sulfation (SULT1A1), whereas hepatic glucuronidation (UGT1A6 and UGT1A9) is immature, achieving adult activity only by 1 to 2 years of age. Cytochrome P450 2E1 (CYP2E1), which generates the hepatotoxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), is also developmentally reduced in neonates, providing relative protection against hepatotoxicity; however, diminished hepatic glutathione reserves require strict weight-based limits.

• Full-Term Neonates (<=28 days of life):
  • Dose: 10 to 12.5 mg/kg/dose PO/IV every 6 to 8 hours.
  • Maximum Daily Dose: 60 mg/kg/day.
  • Preterm infants (<32 weeks PMA): 10 mg/kg/dose PO/IV every 8 to 12 hours (max 40 mg/kg/day).
• Infants and Children (>28 days to 12 years):
  • Dose: 10 to 15 mg/kg/dose PO/IV every 4 to 6 hours (PRN or scheduled).
  • Maximum Daily Dose: 75 mg/kg/day (or 4,000 mg/day, whichever is less).
  • Single Dose Cap: 1,000 mg/dose.
• Adolescents (>=12 years or >=50 kg):
  • Dose: 325 to 1,000 mg PO/IV every 4 to 6 hours; absolute maximum 4,000 mg/day (or 3,000 mg/day in chronic use).
• Formulation Considerations: Intravenous acetaminophen (Ofirmev) bypasses first-pass hepatic metabolism and provides rapid therapeutic plasma levels ($T_{\max} \approx 15 \text{ minutes}$ vs 45–60 minutes for oral). When ordering IV acetaminophen, doses must be specified in milligrams (mg) and volume (mL) to prevent fatal 10-fold vial-administration errors.

2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs block cyclooxygenase (COX-1 and COX-2) enzymes, inhibiting peripheral and central prostaglandin $E_2$ ($PGE_2$) synthesis. They are exceptionally effective for inflammatory pain, somatic trauma, orthopedic procedures, and post-surgical pain.

• Ibuprofen (Oral):
  • Age Approval: Approved for infants >=6 months of age.
  • Rationale for Age Restriction: Neonates and infants <6 months exhibit immature renal hemodynamics. In early infancy, renal blood flow and glomerular filtration rate (GFR) are low and dependent on vasodilatory prostaglandins acting on the afferent arteriole. Inhibiting prostaglandin synthesis with NSAIDs in infants <6 months causes acute renal vasoconstriction, acute kidney injury (AKI), fluid retention, and hyperkalemia.
  • Dose: 10 mg/kg/dose PO every 6 hours (PRN or scheduled).
  • Maximum Daily Dose: 40 mg/kg/day (absolute adult cap: 2,400 mg/day; single dose cap: 800 mg/dose).
• Ketorolac Tromethamine (IV / PO):
  • Age Guidance: Utilized in infants and children >=6 months of age (off-label use in infants 2–6 months requires extreme caution and normal baseline renal function).
  • Dose: 0.5 mg/kg/dose IV every 6 hours (maximum single dose: 15 to 30 mg/dose).
  • Duration Cap: Strict 5-day maximum duration limit across all routes (IV and oral combined) due to compounding risks of gastrointestinal peptic ulceration, platelet dysfunction/post-surgical bleeding, and renal papillary necrosis.
  • Contraindications: Baseline renal impairment (elevated serum creatinine for age), active bleeding or high-risk hemorrhage (post-tonsillectomy, intracranial pathology), uncorrected hypovolemia or dehydration, and concurrent anticoagulation.

---

Opioid Pharmacotherapy in Pediatrics

Opioids are the cornerstone of therapy for moderate-to-severe acute nociceptive, post-operative, and trauma-induced pain. Pediatric patients—particularly neonates and infants <6 months—exhibit heightened sensitivity to opioid-induced respiratory depression due to immature ventilatory responses to hypoxia and hypercapnia, reduced plasma protein binding (lower alpha-1-acid glycoprotein and albumin), and delayed metabolic clearance.

Parenteral Opioid PK/PD Comparison:

┌───────────────┬───────────────────┬────────────────┬─────────────────┬─────────────────────────────────┐
│ Opioid Agent  │ Intermittent IV   │ Peak Effect    │ Duration        │ Key Metabolites & Nuances       │
├───────────────┼───────────────────┼────────────────┼─────────────────┼─────────────────────────────────┤
│ Morphine      │ 0.05–0.1 mg/kg    │ 15–30 minutes  │ 2–4 hours       │ M6G (analgesic), M3G (neurotoxic)│
│ Hydromorphone │ 0.015–0.02 mg/kg  │ 10–20 minutes  │ 3–4 hours       │ 5–7x morphine; no active 6-gluc │
│ Fentanyl      │ 1–2 mcg/kg        │ 3–5 minutes    │ 30–60 minutes   │ Highly lipophilic; chest wall rig│
└───────────────┴───────────────────┴────────────────┴─────────────────┴─────────────────────────────────┘

1. Morphine Sulfate

• Pharmacokinetics & Dosing: Hydrophilic phenanthrene derivative. Intermittent IV dose: 0.05 to 0.1 mg/kg IV every 2 to 4 hours (neonates: 0.025 to 0.05 mg/kg every 4 to 6 hours). Continuous IV infusion in PICU: 10 to 30 mcg/kg/hour.
• Metabolism: Metabolized in the liver via UGT2B7 to morphine-6-glucuronide (M6G, potent analgesic with high mu-affinity) and morphine-3-glucuronide (M3G, non-analgesic; causes neurotoxicity, hyperalgesia, allodynia, and myoclonus). Both metabolites are eliminated via renal glomerular filtration.
• Clinical Trap: In patients with renal failure ($GFR < 30 \text{ mL/min}/1.73\text{ m}^2$), M6G accumulates, causing prolonged, severe respiratory depression, while M3G accumulation induces paradoxical CNS excitation and seizures. Morphine should be dose-reduced by 50% or avoided in renal insufficiency.
• Histamine Release: Morphine stimulates non-immunologic mast cell degranulation, causing peripheral vasodilation, hypotension, bronchospasm, pruritus, and urticaria (frequently mistaken for a true IgE-mediated allergy).

2. Hydromorphone (Dilaudid)

• Potency: Approximately 5 to 7 times more potent than intravenous morphine on a milligram-for-milligram basis.
• Dosing: Intermittent IV dose: 0.015 to 0.02 mg/kg IV every 3 to 4 hours (maximum initial single dose: 1 to 2 mg). Continuous IV infusion: 3 to 5 mcg/kg/hour.
• Metabolism: Glucuronidated via UGT2B7 to hydromorphone-3-glucuronide (H3G). Crucially, hydromorphone lacks an active 6-glucuronide metabolite. It causes negligible histamine release compared to morphine, resulting in less pruritus and hemodynamic instability. Preferred over morphine in patients with renal dysfunction or morphine-induced pruritus.

3. Fentanyl Citrate

• Potency: Approximately 50 to 100 times more potent than morphine.
• Dosing: Intermittent IV dose: 1 to 2 mcg/kg/dose IV every 1 to 2 hours (slow IV push over 3–5 minutes). Continuous infusion: 1 to 3 mcg/kg/hour (titrated up to 5 mcg/kg/hour in mechanically ventilated critical care).
• Pharmacokinetics: Highly lipophilic; crosses the blood-brain barrier within seconds. Onset of action is 1 to 2 minutes; duration of a single bolus is brief (30 to 60 minutes) due to rapid redistribution from brain tissue into peripheral muscle and adipose stores. With prolonged continuous infusions (>48–72 hours), peripheral compartments saturate, resulting in a dramatic increase in the context-sensitive half-life ($t_{1/2} > 15\text{--}24 \text{ hours}$) and prolonged sedation upon discontinuation.
• Chest Wall Rigidity ("Wooden Chest Syndrome"): Rapid intravenous push of fentanyl (especially doses >3–5 mcg/kg or rapid boluses in neonates) induces centrally mediated, severe skeletal muscle rigidity affecting the thorax, diaphragm, and abdominal wall. The vocal cords may spasm and close, rendering bag-valve-mask ventilation impossible.
  • Mechanism: Mediated by mu-opioid receptor stimulation in the locus coeruleus and striatum, triggering descending noradrenergic motor pathway activation.
  • Treatment: Immediate administration of naloxone (0.01 to 0.1 mg/kg IV) or a rapid-acting depolarizing or non-depolarizing neuromuscular blocking agent (rocuronium 0.6–1 mg/kg or succinylcholine 1–2 mg/kg) accompanied by immediate endotracheal intubation.

---

Opioid Equianalgesic Conversions

Converting between parenteral and oral opioid formulations or switching between different opioid molecules requires systematic calculation to avoid under-dosing (precipitating acute withdrawal and pain crisis) or overdosing (fatal respiratory arrest).

Stepwise Protocol for Opioid Equianalgesic Rotation:

Step 1: Calculate Total 24-Hour Opioid Consumption (Basal Infusion + Breakthrough Doses)
                                     │
                                     ▼
Step 2: Convert Current 24-Hour Regimen to Baseline IV Morphine Milligram Equivalents (MME)
                                     │
                                     ▼
Step 3: Convert MME to Target Drug and Desired Route Using Equianalgesic Table Ratios
                                     │
                                     ▼
Step 4: Reduce Calculated Target Dose by 25% to 50% for Incomplete Cross-Tolerance
                                     │
                                     ▼
Step 5: Divide Total Daily Target Dose into Appropriate Interval Regimen (q3h, q4h, or q6h)

Mathematical Rotation Example: Cross-Tolerance Reduction

An 8-year-old child weighing 25 kg is admitted post-thoracotomy receiving a continuous morphine infusion of 0.5 mg/hour and received three supplemental IV breakthrough boluses of 1.5 mg over the last 24 hours. The patient is tolerating enteral feeds, and the team wishes to transition to oral hydromorphone divided every 4 hours.

1. Calculate Total 24-Hour IV Morphine Intake: $\text{Basal: } 0.5 \text{ mg/h} \times 24 \text{ h} = 12 \text{ mg}$ $\text{Breakthrough: } 1.5 \text{ mg} \times 3 = 4.5 \text{ mg}$ $\text{Total 24-Hour IV Morphine} = 12 \text{ mg} + 4.5 \text{ mg} = 16.5 \text{ mg IV Morphine}$
2. Convert IV Morphine to Oral Hydromorphone:
   • Standard Equianalgesic Ratio: $10 \text{ mg IV Morphine} = 7.5 \text{ mg PO Hydromorphone}$ $\text{Calculated Oral Hydromorphone} = 16.5 \text{ mg IV Morphine} \times \left(\frac{7.5 \text{ mg PO Hydromorphone}}{10 \text{ mg IV Morphine}}\right) = 12.375 \text{ mg PO Hydromorphone/day}$
3. Apply Incomplete Cross-Tolerance Reduction:
   • Because mu-opioid receptor conformations and subtype sensitivities differ between drugs, switching to a new opioid carries a risk of fatal overdose due to lack of receptor tolerance. Clinicians must reduce the calculated equianalgesic dose by 25% to 50% (select 30% reduction for well-controlled pain): $\text{Reduced Daily Dose} = 12.375 \text{ mg} \times (1 - 0.30) = 8.66 \text{ mg PO Hydromorphone/day}$
4. Determine Scheduled Interval and Breakthrough Doses:
   • Dosing every 4 hours ($6 \text{ doses/day}$): $\text{Scheduled Dose} = \frac{8.66 \text{ mg}}{6} = 1.44 \text{ mg} \quad \longrightarrow \quad \text{Round to } 1.5 \text{ mg PO every 4 hours scheduled}$
   • Oral breakthrough dose is typically 10% to 15% of total daily dose: $\text{Breakthrough PRN Dose} = 8.66 \text{ mg} \times 0.15 = 1.3 \text{ mg PO every 2 to 3 hours PRN}$

---

Patient-Controlled Analgesia (PCA) vs Nurse-Controlled Analgesia (NCA)

Intravenous patient-controlled analgesia (PCA) allows patients to titrate their analgesia to personal comfort by delivering preset doses at the press of a button. In pediatrics, delivery systems are bifurcated based on cognitive and developmental competence.

PCA vs NCA Programming & Safety Architecture:

┌────────────────────────────┬─────────────────────────────┬─────────────────────────────────┐
│ Modality Parameter         │ PCA (Patient-Controlled)    │ NCA (Nurse-Controlled)          │
├────────────────────────────┼─────────────────────────────┼─────────────────────────────────┤
│ Appropriate Patient Age    │ Developmental Age >= 6–7 yr │ Infants, Toddlers, Non-Verbal   │
│ Button Operator            │ PATIENT ONLY (No family/RN) │ REGISTERED NURSE ONLY           │
│ Demand Bolus Dose          │ Standard weight-based bolus │ Standard weight-based bolus     │
│ Lockout Interval           │ 6 to 10 minutes             │ 15 to 30 minutes (longer safety)│
│ Continuous Basal Rate      │ STRICTLY AVOID in opioid-na │ Selective use in critical care  │
│ Mandatory Safety Monitor   │ Continuous Capnography/EtCO2│ Continuous Capnography/EtCO2    │
└────────────────────────────┴─────────────────────────────┴─────────────────────────────────┘

PCA Qualification & Programming Rules

1. Cognitive Readiness: Children typically achieve the physical dexterity and cognitive understanding required for PCA around 6 to 7 years of age. The child must understand the cause-and-effect relationship between pressing the button and receiving pain relief.
2. "PCA by Proxy" Prohibition: Family members, parents, and visitors must be strictly instructed never to press the PCA button for the child ("PCA by proxy"). Unauthorized button activation by well-meaning caregivers while the patient is sleeping is the single most frequent cause of fatal pediatric PCA-induced respiratory arrest.
3. Basal Infusion Hazards: Continuous background basal infusions should be strictly avoided in opioid-naive pediatric patients. Clinical trials demonstrate that adding a continuous basal rate in opioid-naive children does not improve pain scores or sleep architecture, but significantly increases the incidence of severe hypoventilation, respiratory depression, and oxygen desaturation. Basal rates should be reserved exclusively for opioid-tolerant oncology or sickle cell patients.
4. Lockout Intervals: Standard lockout interval is 6 to 10 minutes for PCA (allowing adequate time for peak IV opioid circulation to reach central nervous system receptors before re-dosing). For NCA, lockouts are typically extended to 15 to 30 minutes to allow full clinical assessment by the bedside nurse.

Standard Pediatric PCA Dosing Guidelines

• Morphine:
  • Demand Dose: 0.015 to 0.03 mg/kg/dose (e.g., 0.02 mg/kg).
  • Lockout Interval: 6 to 10 minutes.
  • Basal Rate (if tolerant): 0.01 to 0.02 mg/kg/hour.
  • 4-Hour Hard Maximum: 0.25 to 0.35 mg/kg.
• Hydromorphone:
  • Demand Dose: 0.003 to 0.005 mg/kg/dose (e.g., 0.004 mg/kg).
  • Lockout Interval: 6 to 10 minutes.
  • Basal Rate (if tolerant): 0.002 to 0.003 mg/kg/hour.
  • 4-Hour Hard Maximum: 0.05 to 0.07 mg/kg.

Capnography Monitoring ($EtCO_2$) vs Pulse Oximetry ($SpO_2$)

• The Clinical Blind Spot of Pulse Oximetry: Post-operative pediatric patients routinely receive supplemental oxygen via nasal cannula. Supplemental oxygen maintains arterial hemoglobin oxygen saturation ($SpO_2 > 95%$) even in the setting of profound hypoventilation or apnea, delaying desaturation alarms until severe, life-threatening hypercapnic respiratory acidosis has already occurred.
• Continuous End-Tidal $CO_2$ ($EtCO_2$) Capnography: Directly measures alveolar ventilation breath-by-breath. Normal $EtCO_2$ is 35 to 45 mmHg.
  • An elevation in $EtCO_2 > 50 \text{ mmHg}$ (hypoventilation/hypercapnia), an abrupt drop in respiratory rate (<8–10 breaths/min), or loss of waveform indicates impending respiratory failure several minutes before $SpO_2$ desaturates, providing an immediate early warning window to discontinue opioid infusions and administer naloxone.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1 (Neonatal Acetaminophen): Do not order acetaminophen at 15 mg/kg every 4 hours or cap at 75 mg/kg/day in a neonate $\le 28$ days of life. Immature glucuronidation restricts neonatal dosing to 10 to 12.5 mg/kg q6–8h with a hard ceiling of 60 mg/kg/day.
• Exam Trap 2 (NSAID Age Limit): Never prescribe ibuprofen to an infant younger than 6 months. Incomplete nephrogenesis and prostaglandin-dependent renal perfusion create severe acute tubular and hemodynamic renal failure.
• Exam Trap 3 (Ketorolac Duration): Watch for surgical orders extending IV ketorolac beyond 5 days. The 5-day cap is absolute; if continued anti-inflammatory therapy is required, transition to oral ibuprofen or celecoxib after day 5.
• Exam Trap 4 (Opioid Conversion Cross-Tolerance): When calculating equianalgesic opioid rotations on board exams, failure to deduct a 25% to 50% cross-tolerance reduction is an automatic error. Unreduced equianalgesic conversions deliver an excessive effective dose to naive receptor subtypes.